Harvard Bioscience
HBIO
HBIO
64 hedge funds and large institutions have $56.4M invested in Harvard Bioscience in 2020 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 21 increasing their positions, 25 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
23% less capital invested
Capital invested by funds: $73.2M → $56.4M (-$16.9M)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Holders
64
Holding in Top 10
2
Calls
–
Puts
–
Top Buyers
| 1 | +$1.74M | |
| 2 | +$1.54M | |
| 3 | +$1.2M | |
| 4 |
Renaissance Technologies
New York
|
+$311K |
| 5 |
GC
Globeflex Capital
San Diego,
California
|
+$177K |
Top Sellers
| 1 | -$865K | |
| 2 | -$648K | |
| 3 | -$607K | |
| 4 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
-$443K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$434K |